Asian Pacific Journal of Cancer Prevention

  • 제15권22호
  • /
  • Pages.9615-9619
  • /
  • 2014
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Lack of Prognostic Value of Human Epidermal Growth Factor- Like Receptor 2 Status in Inflammatory Breast Cancer (IBC): a Meta-analysis

  • Li, Xiu-Juan (Department of General Surgery, Jiangsu Cancer Hospital, The Affiliated Hospital of Nanjing Medical University) ;
  • Zha, Quan-Bin (Department of Oncology, Jintan Hospital Affiliated to Jiangsu University) ;
  • Xu, Xin-Yu (Department of Pathology, Jiangsu Cancer Hospital, The Affiliated Hospital of Nanjing Medical University) ;
  • Xia, Lei (Department of Pathology, Jiangsu Cancer Hospital, The Affiliated Hospital of Nanjing Medical University) ;
  • Zhang, Zhe (Department of Pathology, Jiangsu Cancer Hospital, The Affiliated Hospital of Nanjing Medical University) ;
  • Ren, Zhao-Jun (Department of Pathology, Jiangsu Cancer Hospital, The Affiliated Hospital of Nanjing Medical University) ;
  • Tang, Jin-Hai (Department of General Surgery, Jiangsu Cancer Hospital, The Affiliated Hospital of Nanjing Medical University)
  • 발행 : 2014.12.18
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer which is more likely to be her-2/neu amplified. While the her-2/neu status has been utilised to predict prognosis, the published data are inconsistent. The present meta-analysis was conducted to determine whether the her-2/neu status predicts outcomes. Papers were selected from the PubMed database based on defined inclusion and exclusion criteria. Parameters such as total patients, follow-up time and outcome statistics (i.e. overall survival (OS), relapse-free survival (RFS) were collected. The analysis included 6 studies with 2,838 IBC patients. The summary hazards ratio (HR) estimating the association of OS with HER-2-positive disease was 0.96 (95% confidence interval (95%CI: 0.85-1.10)), with similar findings for RFS (HR=0.81, 95%CI: 0.61-1.09). No obvious statistical heterogeneity was detected. This meta-analysis suggests that HER-2-positive status is not an independent adverse prognostic factor for survival among IBC patient cases.

키워드

참고문헌

  1. Abdul MNA, Razak ZA, Hussain RM, et al (2013). Quantification of Her-2/Neu gene in breast cancer patients using real timepolymerase chain reaction (Q-PCR) and correlation with immunohistochemistry findings. Asian Pac J Cancer Prev, 14, 1655-9. https://doi.org/10.7314/APJCP.2013.14.3.1655
  2. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. https://doi.org/10.2307/2533446
  3. Cabioglu N, Gong Y, Islam R (2007). Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol, 18, 1021-9. https://doi.org/10.1093/annonc/mdm060
  4. Chaher N, Arias-Pulido H, Terki N, et al (2012). Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients. Breast Cancer Res Treat, 131, 437-44. https://doi.org/10.1007/s10549-011-1422-5
  5. Colpaert CG, Vermeulen PB, Benoy I, et al (2003). Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer, 88, 718-25. https://doi.org/10.1038/sj.bjc.6600807
  6. Dawood S, Broglio K, Gong Y, et al (2008). Prognostic Significance of HER-2 Status in women with inflammatory breast cancer. Cancer, 112, 1905-11. https://doi.org/10.1002/cncr.23350
  7. Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, et al (2011). Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol, 29, 1014-21. https://doi.org/10.1200/JCO.2009.27.6543
  8. Gianni L, Pienkowski T, Im YH (2012). Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomized multicentre, openlabel, phase 2 trial. Lancet Oncol, 13, 25-32. https://doi.org/10.1016/S1470-2045(11)70336-9
  9. Hance KW, Anderson WF, Devesa SS (2005). Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the national cancer institute. J Natl Cancer Inst, 97, 966-75. https://doi.org/10.1093/jnci/dji172
  10. Higgins JP, Thompson SG, Deeks JJ, et al (2003) Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
  11. Kim T, Lau J, Erban J (2006). Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes:a systematic review. Clinical Breast Cancer, 7, 386-95. https://doi.org/10.3816/CBC.2006.n.055
  12. Kleer CG, Zhang Y, Pan Q, et al (2002). WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene, 21, 3172-80. https://doi.org/10.1038/sj.onc.1205462
  13. Labidi SI, Mrad K, Mezlini A, et al (2008). Inflammatory breast cancer in Tunisia in the era of multimodality therapy. Ann Oncol, 19, 473-80.
  14. Li J, Gonzalez-Angulo AM, Allen PK, et al (2011). Triplenegative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncol, 16, 1675-83. https://doi.org/10.1634/theoncologist.2011-0196
  15. Low JA, Berman AW, Steinberg SM, et al (2004). Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol, 22, 4067-74. https://doi.org/10.1200/JCO.2004.04.068
  16. Mehta RS, Schubbert T, Kong K (2008). Trastuzumab in inflammatory breast cancer. Ann Oncol, 19, 1815-7. https://doi.org/10.1093/annonc/mdn555
  17. Panades M, Olivotto IA, Speers CH, et al (2004). Evolving treatment strategies for inflammatory breast cancer:a population-based survival analysis. J Clin Oncol, 23, 1941-50.
  18. Rehman S, Reddy CA, Tendulkar RD (2012). Modern outcomes of inflammatory breast cancer. Int J Radiat Oncol Biol Phys, 84, 619-24. https://doi.org/10.1016/j.ijrobp.2012.01.030
  19. Romond EH, Perez EA, Bryant J (2005). Trastuzumab plus adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353, 1673-84. https://doi.org/10.1056/NEJMoa052122
  20. Romond EH, Perez EA, Bryant J, et al (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353, 1673-84. https://doi.org/10.1056/NEJMoa052122
  21. Sawaki M, Ito Y, Akiyama F, et al (2006). High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer. Breast Cancer, 13, 172-8. https://doi.org/10.2325/jbcs.13.172
  22. Slamon DJ, Clark GM, Wong SG, et al (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82. https://doi.org/10.1126/science.3798106
  23. Sutherland S, Ashley S, Walsh G, et al (2010). Inflammatory breast cancer-the royal marsden hospital experience. Cancer, 116, 2815-20. https://doi.org/10.1002/cncr.25178
  24. Tanner M, Isola J, Wiklund T (2006). Topoisomerase IIa gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: scandinavian breast group trial 9401. J Clin Oncol, 24, 2428-36. https://doi.org/10.1200/JCO.2005.02.9264
  25. Tierney JF, Stewart LA, Ghersi D, et al (2007). Practical methods for incorporating summary time-to-event data into metaanalysis. Trials, 8, 16. https://doi.org/10.1186/1745-6215-8-16
  26. Tobias A (1999). Assessing the influence of a single study in the meta-anyalysis estimate. Stata Technical Bulletin, 8, 15-27.
  27. Turpin E, Bieche I, Berthaeau P (2002). The increased incidence of ERBB2 over expression and TP53 mutation in inflammatory breast cancer. Oncogene, 21, 7593-7. https://doi.org/10.1038/sj.onc.1205932
  28. Van Golen KL, Wu ZF, Qiao XT, et al (2000). RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res, 60, 5832-8.
  29. Zell JA, Tsang WY, Taylor TH, et al (2009). Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California cancer registry. Breast Cancer Res, 11, 9.

피인용 문헌

  1. Prognostic Value of Chemotherapy-Induced Amenorrhea in Breast Cancer: a Meta-Analysis vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5939
  2. HER-2 Positive Breast Cancer - a Mini-Review vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.1609